When your symptoms belong to a rare illness, such as Castleman disease (a lymph node disorder), the diagnostic outlook is bleak. Idiopathic multicentric Castleman disease (iMCD) is a life-threatening subtype that affects multiple lymph nodes. With no established diagnostic protocol in place, sufferers may remain undiagnosed – or misdiagnosed with lymphoma or autoimmune disorders – for years. To offer a solution, a multinational team of investigators banded together to pioneer a set of identification criteria (1).
Major Criteria
Minor Criteria
Table 1. Major and minor criteria for the diagnosis of iMCD.
The journey began with a review of 244 clinical cases and 88 lymph node biopsies from iMCD patients. Fifteen months of investigation yielded a set of major and minor criteria for diagnosis (see Table 1). To confirm iMCD, patients must exhibit at least two major and two minor criteria, including at least one abnormal laboratory result. Next, the investigators used their criteria to retrospectively diagnose patients from a clinical trial of siltuximab, a therapeutic tested on iMCD patients. Trial participants who did not meet the criteria had no response to the drug, while those who did had a 43 percent response rate. The outcome seems to show the effectiveness of the criteria, but that doesn’t mean the job is done. Using ACCELERATE, a research platform that collates iMCD clinical data, the researchers aim to keep fine-tuning their method. But even in this early stage, the investigators believe their Castleman criteria could help turn the tide in the fight against iMCD.
Newsletters
Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.
References
- DC Fajgenbaum et al., “International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease”, Blood, [Epub ahead of print] (2017). PMID: 28087540.
